Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy

J Immunol. 2022 Jan 1;208(1):54-62. doi: 10.4049/jimmunol.2100367. Epub 2021 Dec 1.

Abstract

In people with HIV (PWH) on antiretroviral therapy (ART), immune dysfunction persists, including elevated expression of immune checkpoint (IC) proteins on total and HIV-specific T cells. Reversing immune exhaustion is one strategy to enhance the elimination of HIV-infected cells that persist in PWH on ART. We aimed to evaluate whether blocking CTL-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), T cell Ig domain and mucin domain 3 (TIM-3), T cell Ig and ITIM domain (TIGIT) and lymphocyte activation gene-3 (LAG-3) alone or in combination would enhance HIV-specific CD4+ and CD8+ T cell function ex vivo. Intracellular cytokine staining was performed using human PBMCs from PWH on ART (n = 11) and expression of CD107a, IFN-γ, TNF-α, and IL-2 was quantified with HIV peptides and Abs to IC. We found the following: 1) IC blockade enhanced the induction of CD107a and IL-2 but not IFN-γ and TNF-α in response to Gag and Nef peptides; 2) the induction of CD107a and IL-2 was greatest with multiple combinations of two Abs; and 3) Abs to LAG-3, CTLA-4, and TIGIT in combinations showed synergistic induction of IL-2 in HIV-specific CD8+ and CD107a and IL-2 production in HIV-specific CD4+ and CD8+ T cells. These results demonstrate that the combination of Abs to LAG-3, CTLA-4, or TIGIT can increase the frequency of cells expressing CD107a and IL-2 that associated with cytotoxicity and survival of HIV-specific CD4+ and CD8+ T cells in PWH on ART. These combinations should be further explored for an HIV cure.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use*
  • Antigens, CD / immunology
  • Antigens, Viral / immunology
  • CD4-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / immunology*
  • CTLA-4 Antigen / immunology
  • Cells, Cultured
  • Drug Synergism
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Long-Term Survivors
  • HIV-1 / physiology*
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Interleukin-1 / metabolism
  • Lymphocyte Activation
  • Lymphocyte Activation Gene 3 Protein
  • Lysosomal-Associated Membrane Protein 1 / metabolism
  • Male
  • Middle Aged
  • Receptors, Immunologic / immunology
  • T-Cell Antigen Receptor Specificity

Substances

  • Anti-Retroviral Agents
  • Antigens, CD
  • Antigens, Viral
  • CTLA-4 Antigen
  • Immune Checkpoint Inhibitors
  • Interleukin-1
  • Lysosomal-Associated Membrane Protein 1
  • Receptors, Immunologic
  • TIGIT protein, human
  • Lymphocyte Activation Gene 3 Protein